Portal de Periódicos da CAPES

PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

2021; BioMed Central; Volume: 19; Issue: 1 Linguagem: Inglês

10.1186/s12967-021-02937-9

1479-5876

Daniele Santini, Tea Zeppola, Marco Russano, Fabrizio Citarella, Cecilia Anesi, Sebastiano Buti, Marco Tucci, Alessandro Russo, Maria Chiara Sergi, Vincenzo Adamo, Luigia Stefania Stucci, Melissa Bersanelli, Giulia Mazzaschi, Francesco Spagnolo, Francesca Rastelli, Francesca Chiara Giorgi, Raffaele Giusti, Marco Filetti, Paolo Marchetti, Andrea Botticelli, Alain Gelibter, Marco Siringo, Marco Ferrari, Riccardo Marconcini, Maria Giuseppa Vitale, Linda Nicolardi, Rita Chiari, Michele Ghidini, Olga Nigro, Francesco Grossi, Michele De Tursi, Pietro Di Marino, Laura Pala, Paola Queirolo, Sergio Bracarda, Serena Macrini, Stefania Gori, Alessandro Inno, Federica Zoratto, Enrica T. Tanda, Domenico Mallardo, Maria Grazia Vitale, Thomas Talbot, Paolo A. Ascierto, David J. Pinato, Corrado Ficorella, Giampiero Porzio, Alessio Cortellini,

Palliative Care and End-of-Life Issues

The favourable safety profile and the increasing confidence with immune checkpoint inhibitors (ICIs) might have boosted their prescription in frail patients with short life expectancies, who usually are not treated with standard chemotherapy.